



16 November 2020

Dear Prescriber

**Notification of Medicines Shortage for MINIRIN® Nasal Drops
(desmopressin acetate 100 micrograms/mL)**

We wish to advise you of an upcoming supply shortage of MINIRIN (desmopressin acetate) Nasal Drops. This shortage follows a hold in production of Minirin Nasal Drops by the manufacturer.

Supplies of MINIRIN Nasal Drops are currently limited and a supply shortage is estimated to commence by end of December 2020. The duration of this supply shortage is unknown at this time.

MINIRIN Nasal Drops are indicated for:

- Cranial diabetes insipidus (CDI)
- Renal concentrating capacity testing (RCCT)
- Primary nocturnal enuresis (PNE) (from 5 years of age) with normal ability to concentrate urine

Alternative formulations of desmopressin acetate

Ferring anticipates a protracted period to resolve and reinstate production of the intranasal formulations. Consequently, all patients who are currently using MINIRIN Nasal Drops should receive prompt guidance to switch to an alternative treatment.

The following funded desmopressin acetate formulations are not affected by a medicines shortage and are available from pharmacies:

Alternative desmopressin acetate formulation	Funding status for CDI	Funding status for PNE	Funding status for RCCT
Desmopressin-PH&T Nasal spray solution, 0.1 mg/mL	Fully funded	Fully funded	Fully funded
Minirin tablets 0.1mg	Special Authority – funded where intranasal formulations are contraindicated	Special Authority–funded where intranasal formulations are contraindicated	

Alternative desmopressin acetate formulation	Funding status for CDI	Funding status for PNE	Funding status for RCCT
Minirin tablets 0.2mg	Special Authority – funded where intranasal formulations are contraindicated	Special Authority– funded where intranasal formulations are contraindicated	
Minirin injection 4 micrograms/mL	Special Authority – funded where intranasal formulations are contraindicated		Special Authority – funded where intranasal formulations are contraindicated

Information on the recommended dose, approved indications, warnings and contraindications for each of these alternative desmopressin acetate formulations are included in their approved Data Sheets, available at www.medsafe.govt.nz.

Notification of this supply shortage has also been communicated to pharmacists and wholesalers.

Pharmaco sincerely regrets any inconvenience caused to you and your patients.

If you have any questions regarding this notification or if you wish to report any adverse events related to MINIRIN, please contact our Medical Information team on 0800 80 4079 between 9:00 am – 5:00 pm (Eastern Standard Time), Monday to Friday or email at safety@pharmaco.co.nz.

Yours sincerely
PHARMACO (NZ) LTD



Teresa Taylor
HEAD OF REGULATORY, QUALITY & MEDICAL SERVICES

cc Nerissa Ramlall - PHARMAC